Review



rabbit anti cxc motif ligand 1 cxcl1  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Boster Bio rabbit anti cxc motif ligand 1 cxcl1
    EA treatment inhibited the astrocyte and microglia activation in spinal cord of CP rats. ( A ) The IHC staining of microglia in spinal cord of each group. Scale bar=200 μm. ( B ) The protein level of microglia market Iba1 in spinal cord of each group. ( C ) The IHC staining of astrocyte in spinal cord of each group. Scale bar=200 μm. ( D ) The protein level of astrocyte market GFAP in spinal cord of each group. ( E ) Immunofluorescence shows expression of <t>CXCL1</t> (green) and GFAP (red) in rat spinal cord after EA treatment. Data are presented as mean ± SEM, n = 8 rat per group. Bonferroni One-way ANOVA were used for multiple comparisons, ## p < 0.01, ### p < 0.001.
    Rabbit Anti Cxc Motif Ligand 1 Cxcl1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxc motif ligand 1 cxcl1/product/Boster Bio
    Average 91 stars, based on 14 article reviews
    rabbit anti cxc motif ligand 1 cxcl1 - by Bioz Stars, 2026-02
    91/100 stars

    Images

    1) Product Images from "Effects of Electroacupuncture on Alleviating Prostatodynia and Inflammation in Rats with Chronic Nonbacterial Prostatitis"

    Article Title: Effects of Electroacupuncture on Alleviating Prostatodynia and Inflammation in Rats with Chronic Nonbacterial Prostatitis

    Journal: Journal of Pain Research

    doi: 10.2147/JPR.S321119

    EA treatment inhibited the astrocyte and microglia activation in spinal cord of CP rats. ( A ) The IHC staining of microglia in spinal cord of each group. Scale bar=200 μm. ( B ) The protein level of microglia market Iba1 in spinal cord of each group. ( C ) The IHC staining of astrocyte in spinal cord of each group. Scale bar=200 μm. ( D ) The protein level of astrocyte market GFAP in spinal cord of each group. ( E ) Immunofluorescence shows expression of CXCL1 (green) and GFAP (red) in rat spinal cord after EA treatment. Data are presented as mean ± SEM, n = 8 rat per group. Bonferroni One-way ANOVA were used for multiple comparisons, ## p < 0.01, ### p < 0.001.
    Figure Legend Snippet: EA treatment inhibited the astrocyte and microglia activation in spinal cord of CP rats. ( A ) The IHC staining of microglia in spinal cord of each group. Scale bar=200 μm. ( B ) The protein level of microglia market Iba1 in spinal cord of each group. ( C ) The IHC staining of astrocyte in spinal cord of each group. Scale bar=200 μm. ( D ) The protein level of astrocyte market GFAP in spinal cord of each group. ( E ) Immunofluorescence shows expression of CXCL1 (green) and GFAP (red) in rat spinal cord after EA treatment. Data are presented as mean ± SEM, n = 8 rat per group. Bonferroni One-way ANOVA were used for multiple comparisons, ## p < 0.01, ### p < 0.001.

    Techniques Used: Activation Assay, Immunohistochemistry, Immunofluorescence, Expressing



    Similar Products

    rabbit anti cxc motif ligand 1 cxcl1  (Boster Bio)
    91
    Boster Bio rabbit anti cxc motif ligand 1 cxcl1
    EA treatment inhibited the astrocyte and microglia activation in spinal cord of CP rats. ( A ) The IHC staining of microglia in spinal cord of each group. Scale bar=200 μm. ( B ) The protein level of microglia market Iba1 in spinal cord of each group. ( C ) The IHC staining of astrocyte in spinal cord of each group. Scale bar=200 μm. ( D ) The protein level of astrocyte market GFAP in spinal cord of each group. ( E ) Immunofluorescence shows expression of <t>CXCL1</t> (green) and GFAP (red) in rat spinal cord after EA treatment. Data are presented as mean ± SEM, n = 8 rat per group. Bonferroni One-way ANOVA were used for multiple comparisons, ## p < 0.01, ### p < 0.001.
    Rabbit Anti Cxc Motif Ligand 1 Cxcl1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxc motif ligand 1 cxcl1/product/Boster Bio
    Average 91 stars, based on 1 article reviews
    rabbit anti cxc motif ligand 1 cxcl1 - by Bioz Stars, 2026-02
    91/100 stars
    		  Buy from Supplier
    anti gro alpha cxcl1  (Boster Bio)
    90
    Boster Bio anti gro alpha cxcl1
    EA treatment inhibited the astrocyte and microglia activation in spinal cord of CP rats. ( A ) The IHC staining of microglia in spinal cord of each group. Scale bar=200 μm. ( B ) The protein level of microglia market Iba1 in spinal cord of each group. ( C ) The IHC staining of astrocyte in spinal cord of each group. Scale bar=200 μm. ( D ) The protein level of astrocyte market GFAP in spinal cord of each group. ( E ) Immunofluorescence shows expression of <t>CXCL1</t> (green) and GFAP (red) in rat spinal cord after EA treatment. Data are presented as mean ± SEM, n = 8 rat per group. Bonferroni One-way ANOVA were used for multiple comparisons, ## p < 0.01, ### p < 0.001.
    Anti Gro Alpha Cxcl1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti gro alpha cxcl1/product/Boster Bio
    Average 90 stars, based on 1 article reviews
    anti gro alpha cxcl1 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    grα  (Boster Bio)
    90
    Boster Bio grα
    Expression of glucocorticoid receptor and resistance gene at mRNA and protein level in each group. (A) Expression of <t>GRα</t> and β, transforming growth factor-β1 and activator protein-1 mRNA in each group. (B, C) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 protein in each group. Glucocorticoid receptor (GR) α expression was significantly higher in Group VI in comparison with Group III ( ∗ P < 0.05); the expression <t>of</t> <t>GRβ</t> did not differ significantly. Meanwhile, p300 knockdown caused a significant increase in the expression of transforming growth factor-β1 and activator protein-1 at the levels of mRNA and protein, which suggests that p300 is involved in the occurrence of glucocorticoid resistance ( ∗ P < 0.05). Group II: Non-knockout model group; Group III: Non-knockout dexamethasone therapy group; Group VI: p300 knockout dexamethasone therapy group.
    Grα, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/grα/product/Boster Bio
    Average 90 stars, based on 1 article reviews
    grα - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    EA treatment inhibited the astrocyte and microglia activation in spinal cord of CP rats. ( A ) The IHC staining of microglia in spinal cord of each group. Scale bar=200 μm. ( B ) The protein level of microglia market Iba1 in spinal cord of each group. ( C ) The IHC staining of astrocyte in spinal cord of each group. Scale bar=200 μm. ( D ) The protein level of astrocyte market GFAP in spinal cord of each group. ( E ) Immunofluorescence shows expression of CXCL1 (green) and GFAP (red) in rat spinal cord after EA treatment. Data are presented as mean ± SEM, n = 8 rat per group. Bonferroni One-way ANOVA were used for multiple comparisons, ## p < 0.01, ### p < 0.001.

    Journal: Journal of Pain Research

    Article Title: Effects of Electroacupuncture on Alleviating Prostatodynia and Inflammation in Rats with Chronic Nonbacterial Prostatitis

    doi: 10.2147/JPR.S321119

    Figure Lengend Snippet: EA treatment inhibited the astrocyte and microglia activation in spinal cord of CP rats. ( A ) The IHC staining of microglia in spinal cord of each group. Scale bar=200 μm. ( B ) The protein level of microglia market Iba1 in spinal cord of each group. ( C ) The IHC staining of astrocyte in spinal cord of each group. Scale bar=200 μm. ( D ) The protein level of astrocyte market GFAP in spinal cord of each group. ( E ) Immunofluorescence shows expression of CXCL1 (green) and GFAP (red) in rat spinal cord after EA treatment. Data are presented as mean ± SEM, n = 8 rat per group. Bonferroni One-way ANOVA were used for multiple comparisons, ## p < 0.01, ### p < 0.001.

    Article Snippet: Afterwards, the cut segments were incubated with mouse anti-GFAP (MAB360, 1:500, Millipore) and rabbit anti-CXC motif ligand 1 (CXCL1) (BAO21312, 1:200; BOSTER) at 4°C overnight.

    Techniques: Activation Assay, Immunohistochemistry, Immunofluorescence, Expressing

    Expression of glucocorticoid receptor and resistance gene at mRNA and protein level in each group. (A) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 mRNA in each group. (B, C) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 protein in each group. Glucocorticoid receptor (GR) α expression was significantly higher in Group VI in comparison with Group III ( ∗ P < 0.05); the expression of GRβ did not differ significantly. Meanwhile, p300 knockdown caused a significant increase in the expression of transforming growth factor-β1 and activator protein-1 at the levels of mRNA and protein, which suggests that p300 is involved in the occurrence of glucocorticoid resistance ( ∗ P < 0.05). Group II: Non-knockout model group; Group III: Non-knockout dexamethasone therapy group; Group VI: p300 knockout dexamethasone therapy group.

    Journal: Chinese Medical Journal

    Article Title: Role of p300 in the pathogenesis of Henoch-Schonlein purpura nephritis and as a new target of glucocorticoid therapy in mice

    doi: 10.1097/CM9.0000000000000380

    Figure Lengend Snippet: Expression of glucocorticoid receptor and resistance gene at mRNA and protein level in each group. (A) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 mRNA in each group. (B, C) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 protein in each group. Glucocorticoid receptor (GR) α expression was significantly higher in Group VI in comparison with Group III ( ∗ P < 0.05); the expression of GRβ did not differ significantly. Meanwhile, p300 knockdown caused a significant increase in the expression of transforming growth factor-β1 and activator protein-1 at the levels of mRNA and protein, which suggests that p300 is involved in the occurrence of glucocorticoid resistance ( ∗ P < 0.05). Group II: Non-knockout model group; Group III: Non-knockout dexamethasone therapy group; Group VI: p300 knockout dexamethasone therapy group.

    Article Snippet: The primary antibodies used in this study were as follows: GRα (BOSTER Bio Inc, Wuhan, China), GRβ (Bioss Bio Inc, Beijing, China), TGF-β1 (BOSTER Bio Inc), activator protein (AP)-1 (Bioss Bio Inc), and GAPDH (Santa Cruz Bio Inc, Santa Cruz, USA).

    Techniques: Expressing, Comparison, Knockdown, Knock-Out